C4 Therapeutics, Inc.
C4 Therapeutics, Inc. (CCCC) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · CCCC · as of Sep 30, 2025
Ownership Breakdown
103
Institutional Holders
▼ 1 vs Q2
$116.64M
Total Inst. Value
▲ $38.39M vs Q2
82.83M
Shares Outstanding
freeFloat 84.86%
52.54M
13F Shares Held
▼ 2.18M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
CCCC largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
LYNX1 CAPITAL MANAGEMENT LP biological products, (no diagnostic substances) | 7.10M | 10.00% | 10.00% | $15.76B | Nov 13, 2025 | — held |
SOLEUS CAPITAL MANAGEMENT, L.P. biological products, (no diagnostic substances) | 7.05M | 9.93% | 9.93% | $15.66B | Nov 14, 2025 | ▲ 75.0K |
ORBIMED ADVISORS LLC biological products, (no diagnostic substances) | 5.24M | 7.37% | 7.37% | $11.62B | Nov 14, 2025 | ▼ 1.60M |
MORGAN STANLEY biological products, (no diagnostic substances) | 4.97M | 7.00% | 7.00% | $11.04B | May 27, 2026 | ▲ 217.8K |
WASATCH ADVISORS LP biological products, (no diagnostic substances) | 4.85M | 6.83% | 6.83% | $10.77B | Nov 14, 2025 | ▼ 2.57M |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 3.19M | 4.49% | 4.49% | $7.09B | Nov 7, 2025 | ▲ 173.5K |
BANK OF AMERICA CORP /DE/ biological products, (no diagnostic substances) | 2.05M | 2.89% | 2.89% | $4.56B | Feb 3, 2026 | ▲ 45.2K |
MILLENNIUM MANAGEMENT LLC biological products, (no diagnostic substances) | 1.93M | 2.72% | 2.72% | $4.29B | Nov 14, 2025 | ▲ 832.9K |
SILVERARC CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 1.90M | 2.67% | 2.67% | $4.21B | Nov 12, 2025 | ▲ 1.90M |
BLACKROCK, INC. biological products, (no diagnostic substances) | 1.60M | 2.25% | 2.25% | $3.54B | Nov 12, 2025 | ▼ 233.0K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
18
Increased
+4.55M shares8
New Positions
first time holders17
Decreased
−5.75M shares0
Sold Out
fully exitedNet shares change (top 50)
1.20M
+4.55M / −5.75M
Net new holders
+9
8 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
CCCC insider trading · insider activity
Source: SEC Form 4
2
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Anderson Kenneth Carl director | Apr 1, 2026 | Award | 4,259 | $2.70 | $11.5K | 68.2K | Form 4 ↗ |
GROGAN DONNA ROY director | Apr 1, 2026 | Award | 5,370 | $2.70 | $14.5K | 71.5K | Form 4 ↗ |
Boyle Scott N Chief Business Officer | Feb 13, 2026 | Award | 200,000 | — | — | 307.8K | Form 4 ↗ |
Boyle Scott N Chief Business Officer | Feb 13, 2026 | Tax Withhold | 1,735 | $1.89 | $3.3K | 306.1K | Form 4 ↗ |
Boyle Scott N Chief Business Officer | Feb 14, 2026 | Tax Withhold | 7,269 | $1.89 | $13.7K | 298.8K | Form 4 ↗ |
Mahaney Paige Chief Scientific Officer | Feb 13, 2026 | Award | 240,000 | — | — | 339.4K | Form 4 ↗ |
Mahaney Paige Chief Scientific Officer | Feb 14, 2026 | Tax Withhold | 2,446 | $1.89 | $4.6K | 336.9K | Form 4 ↗ |
Schick Kelly Chief People Officer | Feb 13, 2026 | Award | 200,000 | — | — | 308.9K | Form 4 ↗ |
Schick Kelly Chief People Officer | Feb 13, 2026 | Tax Withhold | 1,735 | $1.89 | $3.3K | 307.1K | Form 4 ↗ |
Schick Kelly Chief People Officer | Feb 14, 2026 | Tax Withhold | 7,269 | $1.89 | $13.7K | 299.9K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
C4 Therapeutics, Inc. (CCCC) is primarily owned by institutional investors, who hold approximately 63.4% of total shares outstanding. Company insiders own approximately 15.14%, while retail and public investors account for the remaining 21.42%.
The largest institutional shareholder of C4 Therapeutics, Inc. is LYNX1 CAPITAL MANAGEMENT LP, holding approximately 7.10 million shares — equal to 10.00% of outstanding shares — as of September 30, 2025.
A total of 103 institutional investors currently hold CCCC stock, with a combined institutional value of approximately $116,636,299 as of the most recent 13F filing period.
Frequently asked questions
CCCC ownershipC4 Therapeutics, Inc. (CCCC) is primarily owned by institutional investors, who hold approximately 63.4% of shares. The largest shareholder is LYNX1 CAPITAL MANAGEMENT LP with a 10.00% stake. Company insiders hold 15.14%. Data sourced from SEC Form 13F as of September 30, 2025.